RESEARCHER PROFILE (Filmed November 2023)
Dr Felicity Han, Research Fellow
Australian Institute for Bioengineering and Nanotechnology
University of Queensland, Australia
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
Dr Han’s team have developed five different techniques to produce painkiller-loaded nanoparticles and nanofibers aimed at improving pain relief for patients where available pain-killers either lack efficacy or produce dose-limiting side-effects. With the use of their nanoparticles, Dr Han’s team aim to turn a small but potent peptide that has been on the market for over a decade into an oral treatment for improving pain management that currently lacks efficacy in patients. T
Dr Han’s research focuses on developing drug-products to solve one of the largest unmet medical needs in the pain field through the use of sustainable materials. Her team are currently working on developing multifunctional sutures including biodegradable pain relief sutures and innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. Their research also investigates the role of C5a and C3a in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain, and OA pain.
Dr Han works in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. They also provide a preclinical evaluation of novel compounds and formulations.
Dr Han enjoy’s volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). Currently, she is serving as a guest editor of Pain Research and Management.
-
Environmental exposure to function of lung epithelial stem cell biology
Dr Clare Weeden has recently commenced as a Laboratory Head at WEHI in 2025, supported by the CSL Centenary Fellowship.
Dr Weeden specialises in lung epithelial cell biology in the context of homeostasis, inflammation, and lung cancer, particularly in people who don’t smoke. Her work endeavours to understand how past environmental exposures shape the responses of lung cells and the molecular mechanisms underlying this cellular recall, with the aim to develop novel early detection strategies for lung disease.
-
Supportive care for people living with or beyond cancer treatment
Dr Hannah Wardill is a Hospital Research Foundation Fellow and lead of the Supportive Oncology Research Group (SORG), in the School of Biomedicine, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI). She is an Executive Board Member of the Multinational Association for Supportive Care in Cancer / International Society for Oral Oncology (MASCC/ISOO) and Chair of both MASCC/ISOO Patient Partnership Committee & the Palliative Care Clinical Studies Collaborative (PaCCSC) Cancer Symptom Trials (Gut Dysfunction Node; supported by Cancer Australia).
-
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
